Neurologia最新文献

{"title":"Quality of life and mental health in young strokes","authors":"D. Alonso Modino ,&nbsp;L. Perestelo Pérez ,&nbsp;F.M. Rosa González ,&nbsp;A. Toledo Chavarri ,&nbsp;C. Valcarcel Nazco ,&nbsp;F.I. Montón Álvarez","doi":"10.1016/j.nrleng.2025.03.003","DOIUrl":"10.1016/j.nrleng.2025.03.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Stroke has a significant impact on mental health and health-related quality of life (HRQoL); these aspects have not been sufficiently studied in young stroke.</div></div><div><h3>Objectives</h3><div>To evaluate HRQoL, mental health, and the relationship between these variables and the incorporation of young adults into working life after stroke.</div></div><div><h3>Material and methods</h3><div>We conducted a prospective descriptive study of patients with JS between 2016 and 2017, using such questionnaires and scales as EuroQol-5D, the 36-item Short Form Health Survey, National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), 12-item General Health Questionnaire, Hamilton Anxiety and Depression Rating Scales, and BURQOL-meter; tests were administered at 2 interviews, held 6 and 12 months after stroke.</div></div><div><h3>Results</h3><div>We analysed 41 patients, with a mean age of 41.8 years. At one year, the mean NIHSS score was 0.54 and mRS score was 0–2 in 95.1%. No differences were observed over time in quality of life or mental health scales. Prevalence rates for depression and anxiety at one year were 46.3% and 41.5%, respectively. Male sex and active employment were associated with better HRQoL. A total of 41.5% of patients were in work at one year after the stroke. Statistically significant associations were observed between quality of life, mental health, and incorporation into working life.</div></div><div><h3>Conclusions</h3><div>Young stroke affects HRQoL, and patients are at high risk of anxiety and depression, underdiagnosed and undertreated disorders that affect quality of life and the return to work, which decreases after stroke in young adults.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 229-238"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143675044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge about oral preventive treatments in patients with migraine: A nationwide study","authors":"A. López-Bravo ,&nbsp;S. Quintas ,&nbsp;A. Mínguez-Olaondo ,&nbsp;A. Alpuente ,&nbsp;C. Nieves-Castellanos ,&nbsp;M. Pilar Navarro-Pérez ,&nbsp;S. Pérez-Pereda ,&nbsp;A. Layos Romero ,&nbsp;C. Calle de Miguel ,&nbsp;D. García-Azorín ,&nbsp;M. Torres-Ferrús ,&nbsp;S. Santos-Lasaosa","doi":"10.1016/j.nrleng.2025.03.006","DOIUrl":"10.1016/j.nrleng.2025.03.006","url":null,"abstract":"<div><h3>Background</h3><div>Patients’ knowledge about their medications is key to guarantee therapeutic compliance in chronic diseases.</div></div><div><h3>Aims of the study</h3><div>To determine patients’ knowledge of oral preventive treatment (OPT) in migraine.</div></div><div><h3>Methods</h3><div>This is a cross-sectional study evaluating knowledge of medication with a validated questionnaire that assessed: therapeutic objective, process of use, safety and conservation.</div></div><div><h3>Results</h3><div>198 patients were included. Mean age was 45.4 ± 11.5 years-old and 92.4% were women. A 61.1% of migraine patients did not know the medication they used, 55.1% showed insufficient knowledge and 6.1% had no knowledge. The most known dimension was conservation (80.3%) and the most unknown dimension of was safety (33.7%). In this regard, 82.3% considered that they should not take precautions when taking the treatment, 80.3% stated that it had no contraindications and 82.8% were unaware of possible interactions with other medications. Worse knowledge about OPT was associated with longer time since migraine onset (<em>p</em> = .049), higher scores on the Hospital Anxiety and Depression Scale (<em>p</em> = .021), less qualified jobs (<em>p</em> = .045), use of monotherapy (<em>p</em> = .001) and longer periods since OPT initiation (<em>p</em> = .013).</div></div><div><h3>Conclusions</h3><div>The majority of migraine patients did not adequately know their preventive treatment, despite identifying some of the items related to their medication. The present study shows that knowledge of patients about their preventive treatment should be evaluated in clinical practice and could help migraine patients in the correct use of OPT.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 249-255"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143675112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lingual dystonia: response to botulinum toxin treatment","authors":"A. Fernández Revuelta,&nbsp;E. López Valdés,&nbsp;R. García-Ramos","doi":"10.1016/j.nrleng.2025.03.005","DOIUrl":"10.1016/j.nrleng.2025.03.005","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 331-332"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143675041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliable change indices for 16 neuropsychological tests at six different time points","authors":"O. Sáez-Atxukarro ,&nbsp;J. Peña ,&nbsp;R. del Pino ,&nbsp;N. Ibarretxe-Bilbao ,&nbsp;N. Ojeda","doi":"10.1016/j.nrleng.2025.03.007","DOIUrl":"10.1016/j.nrleng.2025.03.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuropsychological assessment often involves repeated testing in order to assess a cognitive change or conduct a longitudinal follow-up study of a patient. To assess whether the change between assessments is relevant or not, longitudinal reference data are needed. The aim of this study is to provide reference data to enable interpretation of score changes between assessments for 16 commonly used tests, at six different time intervals between successive assessments, using five reliable change indices.</div></div><div><h3>Methods</h3><div>The study is part of the Normacog project, in which 388 healthy participants recruited in Spain (aged 18–84 years) were assessed on two occasions. A baseline assessment was carried out, and then followed up at 1 month (<em>n</em> <!-->=<!--> <!-->67), 3 months (<em>n</em> <!-->=<!--> <!-->64), 6 months (<em>n</em> <!-->=<!--> <!-->59), 9 months (<em>n</em> <!-->=<!--> <!-->60), 12 months (<em>n</em> <!-->=<!--> <!-->68), or 24 months (<em>n</em> <!-->=<!--> <!-->70). Longitudinal data were analyzed, and reliable change indices were calculated.</div></div><div><h3>Results</h3><div>A significant improvement was observed between assessment scores for all time points, especially in memory-related variables. Reference data are provided using the following indices: discrepancy scores expressed in percentiles, standard deviation index (SDI), reliable change index (RCI), RCI<!--> <!-->+<!--> <!-->practice effect (RCI<!--> <!-->+<!--> <!-->PE), and standardized regression-based formulae.</div></div><div><h3>Conclusions</h3><div>This study provides data to analyze whether or not a cognitive change can be considered reliable. The results support the use of these reliable change indices to avoid biases related to successive assessments. This study will lay the foundations for the implementation of these tools in clinical practice, and will be a reference for the creation of reliable change indices.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 256-278"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular dynamics of amyloid-β transport in Alzheimer's disease: Exploring therapeutic plasma exchange with albumin replacement – Current insights and future perspectives","authors":"R. Mondal ,&nbsp;S. Deb ,&nbsp;G. Shome ,&nbsp;V. Sarkar ,&nbsp;D. Lahiri ,&nbsp;S.S. Datta ,&nbsp;J. Benito-León","doi":"10.1016/j.nrleng.2025.03.008","DOIUrl":"10.1016/j.nrleng.2025.03.008","url":null,"abstract":"<div><h3>Introduction</h3><div>The complex process of amyloid-β (Aβ) transportation across the blood–brain and blood–cerebrospinal fluid barriers is crucial for preventing Aβ accumulation, which linked to dementia and neurodegeneration. This review explores therapeutic plasma exchange with albumin replacement in Alzheimer's disease, based on the dynamics of amyloid-β between the brain, plasma, and cerebrospinal fluid.</div></div><div><h3>Methodology</h3><div>A comprehensive literature review was conducted using PubMed/Medline, Cochrane Library, and open databases (bioRxiv, MedRixv, preprint.org) up to April 30, 2023. The first search utilized the following MeSH terms and keywords: ‘Plasma Exchange’, ‘Plasmapheresis’, ‘Therapeutic plasma exchange’, ‘Apheresis’, ‘Aβ’, ‘p-tau’, ‘Total-tau’, ‘Alzheimer's disease’, ‘Cognitive dysfunction’, ‘neurodegenerative diseases’, ‘centrifugation’, ‘membranous’, and ‘filtration’ in the Title/Abstract, yielding 146 results. A second search with the keywords: ‘Albumin’, ‘Aβ’, ‘BBB’, ‘Alzheimer's dementia’, and ‘Nerve degeneration’ resulted in 125 additional articles for analysis. Finally, a third search using keywords: ‘Albumin structural domains’, ‘Albumin-Aβ interactions’, ‘Albumin-endothelial interactions’, and ‘Post-Translational Modification’ produced 193 results for further review.</div></div><div><h3>Results/Discussion</h3><div>Therapeutic plasma exchange shows potential as a disease-modifying therapy for dementia, specifically for Alzheimer's disease. Additionally, the promising role of albumin supplementation in cognitive improvement has attracted attention. However, clinical evidence supporting therapeutic plasma exchange for dementia remains limited, necessitating further research and development to mitigate potential adverse effects. A deeper understanding of the molecular dynamics of Aβ transportation and the mechanisms of therapeutic plasma exchange is essential. A critical evaluation of existing evidence highlights the importance of balancing potential benefits with associated risks, which will guide the development and application of these treatments in neurodegenerative diseases.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 306-328"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease","authors":"R. Sivera Mascaró ,&nbsp;T. García Sobrino ,&nbsp;A. Horga Hernández ,&nbsp;A.L. Pelayo Negro ,&nbsp;A. Alonso Jiménez ,&nbsp;A. Antelo Pose ,&nbsp;M.D. Calabria Gallego ,&nbsp;C. Casasnovas ,&nbsp;C.A. Cemillán Fernández ,&nbsp;J. Esteban Pérez ,&nbsp;M. Fenollar Cortés ,&nbsp;M. Frasquet Carrera ,&nbsp;M.P. Gallano Petit ,&nbsp;A. Giménez Muñoz ,&nbsp;G. Gutiérrez Gutiérrez ,&nbsp;A. Gutiérrez Martínez ,&nbsp;R. Juntas Morales ,&nbsp;N.L. Ciano-Petersen ,&nbsp;P.L. Martínez Ulloa ,&nbsp;S. Mederer Hengstl ,&nbsp;T. Sevilla Mantecón","doi":"10.1016/j.nrleng.2024.02.008","DOIUrl":"10.1016/j.nrleng.2024.02.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Charcot-Marie-Tooth disease (CMT) is classified according to neurophysiological and histological findings, the inheritance pattern, and the underlying genetic defect. The objective of these guidelines is to offer recommendations for the diagnosis, prognosis, follow-up, and treatment of this disease in Spain.</div></div><div><h3>Material and methods</h3><div>These consensus guidelines were developed through collaboration by a multidisciplinary panel encompassing a broad group of experts on the subject, including neurologists, paediatric neurologists, geneticists, physiatrists, and orthopaedic surgeons.</div></div><div><h3>Recommendations</h3><div>The diagnosis of CMT is clinical, with patients usually presenting a common or classical phenotype. Clinical assessment should be followed by an appropriate neurophysiological study; specific recommendations are established for the parameters that should be included. Genetic diagnosis should be approached sequentially; once <em>PMP22</em> duplication has been ruled out, if appropriate, a next-generation sequencing study should be considered, taking into account the limitations of the available techniques. To date, no pharmacological disease-modifying treatment is available, but symptomatic management, guided by a multidiciplinary team, is important, as is proper rehabilitation and orthopaedic management. The latter should be initiated early to identify and improve the patient’s functional deficits, and should include individualised exercise guidelines, orthotic adaptation, and assessment of conservative surgeries such as tendon transfer. The follow-up of patients with CMT is exclusively clinical, and ancillary testing is not necessary in routine clinical practice.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 3","pages":"Pages 290-305"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focusing on post-COVID syndrome fatigue","authors":"M. Gómez-Eguílaz ,&nbsp;S. López-Alava ,&nbsp;J.L. Ramón-Trapero ,&nbsp;F. Castillo-Álvarez ,&nbsp;N. Gómez Loizaga ,&nbsp;C. García-Penco ,&nbsp;N. Boukichou-Abdelkader ,&nbsp;L. Pérez-Martínez","doi":"10.1016/j.nrleng.2025.02.002","DOIUrl":"10.1016/j.nrleng.2025.02.002","url":null,"abstract":"<div><h3>Introduction</h3><div>More than 100 million people worldwide have been infected by SARS-CoV-2 virus, the virus responsible for the acute disease COVID-19. Multiple studies have shown how various symptoms in these patients can persist for several months after resolution of the acute process, a phenomenon known as post-COVID syndrome. Neurological symptoms are varied, but the great majority of patients present fatigue.</div></div><div><h3>Objective</h3><div>To analyse post-COVID fatigue.</div></div><div><h3>Methods</h3><div>We present a prospective, single-centre, case-control study comparing patients with fatigue in the context of post-COVID syndrome with patients with history of COVID-19 but without post-COVID fatigue. Data were recorded at baseline (April 2021) and at 6 months. Data were recorded on clinical variables, fatigue questionnaires, sleep disorders, depression, anxiety, cognitive impairment, and quality of life. Basic laboratory analysis was performed with blood samples collected at the 2 visits. In addition, a substudy of proinflammatory (IL-6, IL-1β, TNF-α) and anti-inflammatory (IL-10) cytokines was performed.</div></div><div><h3>Results</h3><div>Fatigue as measured by the Chalder Fatigue Scale was mixed (physical and psychological) and of moderate intensity. At 6 months, physical fatigue improved, but psychological fatigue did not. Significant differences were found in sleepiness, cognitive impairment, anxiety, and quality of life. Significant alterations were observed in TNF-α levels, but not in the remaining cytokines.</div></div><div><h3>Conclusions</h3><div>Patients with fatigue presented a poorer quality of life, with an improvement being observed at 6 months, which suggests a course that may be self-limiting; however, this will have to be confirmed with longer studies.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 2","pages":"Pages 204-215"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opsoclonus-myoclonus syndrome and prostate cancer. An entity to be aware of","authors":"C. Guijarro-Castro ,&nbsp;L. Estallo-Guijarro","doi":"10.1016/j.nrleng.2024.02.004","DOIUrl":"10.1016/j.nrleng.2024.02.004","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 2","pages":"Pages 216-217"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selection of patients for percutaneous closure in nonlacunar cryptogenic stroke associated with patent foramen ovale. Data from the NORDICTUS cooperative registry","authors":"J. Tejada García ,&nbsp;L.B. Lara Lezama ,&nbsp;R. de la Fuente Blanco ,&nbsp;A. Pérez de Prado ,&nbsp;L. Benavente Fernández ,&nbsp;M. Rico Santos ,&nbsp;M.D. Fernández Couto ,&nbsp;L. Naya Ríos ,&nbsp;I. Couso Pazó ,&nbsp;P.V. Alba ,&nbsp;L. Redondo-Robles ,&nbsp;L. López Mesonero ,&nbsp;S. Arias-Rivas ,&nbsp;M. Santamaría Cadavid ,&nbsp;H. Tejada Meza ,&nbsp;L. Horna Cañete ,&nbsp;I. Azkune Calle ,&nbsp;A. Pinedo Brochado ,&nbsp;J.M. García Sánchez ,&nbsp;I. Caballero Romero ,&nbsp;M. Martínez Zabaleta","doi":"10.1016/j.nrleng.2022.09.008","DOIUrl":"10.1016/j.nrleng.2022.09.008","url":null,"abstract":"<div><h3>Introduction</h3><div>There is an extending use of percutaneous closure of patent foramen ovale (PFO) as therapy for PFO-associated cryptogenic strokes. The aim of our study was to investigate the clinical practice of percutaneous closure of PFO and to analyse the variables for decision-making on the selection of patients for this procedure.</div></div><div><h3>Method</h3><div>A prospective observational multicentric survey was conducted using all the cases of cryptogenic stroke/transient ischaemic attack associated with PFO recorded in the NORDICTUS hospital registry during the period 2018-2021. Clinical data, radiological patterns, echocardiogram data and factors related to PFO-associated stroke (thromboembolic disease and paradoxical embolism criteria) were recorded. The indication for closure was analysed according to age (≤/&gt; 60 years) and the characteristics of the PFO.</div></div><div><h3>Results</h3><div>In the group ≤ 60 years (n = 488), 143 patients (29.3%) underwent PFO closure. The most influential variables for this therapy were detection of a high-risk PFO (OR 4.11; IC 2.6-6.5, <em>P</em> &lt; .001), criteria for paradoxical embolism (OR 2.61; IC 1.28−5.28; <em>P</em> = .008) and previous use of antithrombotics (OR 2.67; IC 1.38−5.18; <em>P</em> = .009). In the &gt; 60 years group (n = 124), 24 patients had PFO closure (19%). The variables related to this option were history of pulmonary thromboembolism, predisposition to thromboembolic disease, paradoxical embolism criteria, and high-risk PFO.</div></div><div><h3>Conclusions</h3><div>The detection of a high-risk PFO (large shunt, shunt with associated aneurysm) is the main criterion for a percutaneous closure-based therapy. Other conditions to consider in the eligibility of patients are the history of thromboembolic disease, paradoxical embolism criteria or the previous use of antithrombotics.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 2","pages":"Pages 139-149"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40474072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dopamine agonist therapy in Parkinson’s disease: Spanish expert consensus on its use in different clinical situations","authors":"D. Santos García ,&nbsp;J. Pagonabarraga Mora ,&nbsp;F. Escamilla Sevilla ,&nbsp;P.J. García Ruiz ,&nbsp;J. Infante Ceberio ,&nbsp;J. Kulisevsky Bojarski ,&nbsp;G. Linazasoro Cristóbal ,&nbsp;M.R. Luquín Piudo ,&nbsp;J.C. Martínez Castrillo ,&nbsp;S. Jesús Maestre ,&nbsp;L. Vela Desojo ,&nbsp;F.J. Campos Lucas ,&nbsp;F. Caballero Martínez ,&nbsp;P. Mir ,&nbsp;Panel of Experts Phase 1","doi":"10.1016/j.nrleng.2023.04.008","DOIUrl":"10.1016/j.nrleng.2023.04.008","url":null,"abstract":"<div><h3>Background</h3><div>Different types of therapies were proven effective for the medical management of motor and non-motor symptoms in Parkinson’s disease (PD). We aimed to gain consensus on the dopamine agonist (DA) therapy use in different clinical scenarios of Parkinson’s disease (PD) patients.</div></div><div><h3>Methods</h3><div>This consensus study was based on the nominal group technique. Initially, a consensus group comprising 12 expert neurologists in the PD field identified the topics to be addressed and elaborated different evidence-based preliminary statements. Next, a panel of 48 Spanish neurologists expressed their opinion on an internet-based systematic voting program. Finally, initial ideas were reviewed and rewritten according to panel contribution and were ranked by the consensus group using a Likert-type scale. The analysis of data was carried out by using a combination of both qualitative and quantitative methods. The consensus was achieved if the statement reached ≥ 3.5 points in the voting process.</div></div><div><h3>Results</h3><div>The consensus group produced 76 real-world recommendations. The topics addressed included 12 statements related to DA therapy in early PD, 20 statements concerning DA treatment strategy in patients with motor complications, 11 statements associated with DA drugs and their side effects, and 33 statements regarding DA therapy in specific clinical scenarios. The consensus group did not reach a consensus on 15 statements.</div></div><div><h3>Conclusion</h3><div>The findings from this consensus method represent an exploratory step to help clinicians and patients in the appropriate use of DA in different stages and clinical situations of PD.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 2","pages":"Pages 171-181"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9779042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}